Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0H2RJ
|
|||
Former ID |
DNCL001903
|
|||
Drug Name |
Clazosentan
|
|||
Synonyms |
Clazosentan; 180384-56-9; Ro-61-1790; VML-588; UNII-3DRR0X4728; AXV-343434; CHEMBL109648; 3DRR0X4728; Clazosentan [INN]; VML 588; AXV 034; AXV-034343; Ro 61-1790; AXV-034; AXV 034343; AC1O5FK3; SCHEMBL1652657; CTK4D7597; DTXSID60170955; ZINC3939238; BDBM50066370; AKOS032946377; SB18855; N-[6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)-2-[2-(2H-TETRAZOL-5-YL)-4-PYRIDINYL]-4-PYRIMIDINYL]-5-METHYL-2-PYRIDINESULFONAMIDE; DB-065318; FT-0765561
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Cerebral vasospasm [ICD-11: BA85.Z; ICD-9: 443.9] | Phase 3 | [1], [2] | |
Vasospasm [ICD-11: 9B74.0] | Discontinued in Phase 3 | [3] | ||
Company |
Actelion Pharmaceuticals
|
|||
Structure |
Download2D MOL |
|||
Formula |
C25H23N9O6S
|
|||
Canonical SMILES |
CC1=CN=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=CC(=NC=C3)C4=NNN=N4)OCCO)OC5=CC=CC=C5OC
|
|||
InChI |
1S/C25H23N9O6S/c1-15-7-8-20(27-14-15)41(36,37)32-24-21(40-19-6-4-3-5-18(19)38-2)25(39-12-11-35)29-22(28-24)16-9-10-26-17(13-16)23-30-33-34-31-23/h3-10,13-14,35H,11-12H2,1-2H3,(H,28,29,32)(H,30,31,33,34)
|
|||
InChIKey |
LFWCJABOXHSRGC-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 180384-56-9
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Endothelin A receptor (EDNRA) | Target Info | Antagonist | [4] |
Endothelin receptor (EDNR) | Target Info | Antagonist | [1], [2] | |
KEGG Pathway | Calcium signaling pathway | |||
cGMP-PKG signaling pathway | ||||
cAMP signaling pathway | ||||
Neuroactive ligand-receptor interaction | ||||
Vascular smooth muscle contraction | ||||
Renin secretion | ||||
Pathways in cancer | ||||
NetPath Pathway | IL4 Signaling Pathway | |||
Panther Pathway | Endothelin signaling pathway | |||
Pathway Interaction Database | Endothelins | |||
EGFR-dependent Endothelin signaling events | ||||
Reactome | Peptide ligand-binding receptors | |||
G alpha (q) signalling events | ||||
WikiPathways | Prostaglandin Synthesis and Regulation | |||
GPCRs, Class A Rhodopsin-like | ||||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
Peptide GPCRs | ||||
Endothelin Pathways | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
GPCRs, Other |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017374) | |||
REF 4 | Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subar... Acta Neurochir (Wien). 2007;149(9):911-8; discussion 918. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.